Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo.
Identifieur interne : 000020 ( France/Analysis ); précédent : 000019; suivant : 000021Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo.
Auteurs : Sébastien D S. Pion [France] ; Cédric B. Chesnais [France] ; Gary J. Weil [États-Unis] ; Peter U. Fischer [États-Unis] ; François Missamou [République du Congo] ; Michel Boussinesq [République du Congo]Source :
- The Lancet. Infectious diseases [ 1474-4457 ] ; 2017.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Albendazole (administration et posologie), Albendazole (usage thérapeutique), Animaux, Antihelminthiques (administration et posologie), Antihelminthiques (usage thérapeutique), Antiparasitaires (effets indésirables), Antiparasitaires (usage thérapeutique), Enfant, Facteurs temps, Femelle, Filariose lymphatique (parasitologie), Filariose lymphatique (traitement médicamenteux), Fèces (parasitologie), Helminthiase (parasitologie), Helminthiase (traitement médicamenteux), Humains, Ivermectine (effets indésirables), Ivermectine (usage thérapeutique), Loase (), Mâle, Sol (parasitologie).
- MESH :
- administration et posologie : Albendazole, Antihelminthiques.
- effets indésirables : Antiparasitaires, Ivermectine.
- parasitologie : Filariose lymphatique, Fèces, Helminthiase, Sol.
- traitement médicamenteux : Filariose lymphatique, Helminthiase.
- usage thérapeutique : Albendazole, Antihelminthiques, Antiparasitaires, Ivermectine.
- Adolescent, Adulte, Animaux, Enfant, Facteurs temps, Femelle, Humains, Loase, Mâle.
English descriptors
- KwdEn :
- Adolescent, Adult, Albendazole (administration & dosage), Albendazole (therapeutic use), Animals, Anthelmintics (administration & dosage), Anthelmintics (therapeutic use), Antiparasitic Agents (adverse effects), Antiparasitic Agents (therapeutic use), Child, Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (parasitology), Feces (parasitology), Female, Helminthiasis (drug therapy), Helminthiasis (parasitology), Humans, Ivermectin (adverse effects), Ivermectin (therapeutic use), Loiasis (complications), Male, Soil (parasitology), Time Factors.
- MESH :
- chemical , administration & dosage : Albendazole, Anthelmintics.
- chemical , adverse effects : Antiparasitic Agents, Ivermectin.
- chemical , parasitology : Soil.
- chemical , therapeutic use : Albendazole, Anthelmintics, Antiparasitic Agents, Ivermectin.
- complications : Loiasis.
- drug therapy : Elephantiasis, Filarial, Helminthiasis.
- parasitology : Elephantiasis, Filarial, Feces, Helminthiasis.
- Adolescent, Adult, Animals, Child, Female, Humans, Male, Time Factors.
Abstract
The standard treatment strategy of mass drug administration with ivermectin plus albendazole for lymphatic filariasis cannot be applied in central Africa, because of the risk of serious adverse events in people with high Loa loa microfilaraemia. Thus, alternative strategies are needed. We investigated one such alternative strategy for mass drug administration for elimination of lymphatic filariasis and soil-transmitted helminth infections in Republic of the Congo.
DOI: 10.1016/S1473-3099(17)30175-5
PubMed: 28372977
Affiliations:
- France, République du Congo, États-Unis
- Languedoc-Roussillon, Missouri (État), Occitanie (région administrative)
- Montpellier, Saint-Louis (Missouri)
- École de médecine (Université Washington de Saint-Louis)
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000266
- to stream PubMed, to step Curation: 000266
- to stream PubMed, to step Checkpoint: 000266
- to stream Ncbi, to step Merge: 008F44
- to stream Ncbi, to step Curation: 008F44
- to stream Ncbi, to step Checkpoint: 008F44
- to stream Main, to step Merge: 000620
- to stream Main, to step Curation: 000619
- to stream Main, to step Exploration: 000619
- to stream France, to step Extraction: 000020
Links to Exploration step
pubmed:28372977Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo.</title><author><name sortKey="Pion, Sebastien D S" sort="Pion, Sebastien D S" uniqKey="Pion S" first="Sébastien D S" last="Pion">Sébastien D S. Pion</name><affiliation wicri:level="3"><nlm:affiliation>Institut de Recherche pour le Développement, UMI233/INSERM U1175, Université de Montpellier, Montpellier, France. Electronic address: sebastien.pion@ird.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherche pour le Développement, UMI233/INSERM U1175, Université de Montpellier, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Chesnais, Cedric B" sort="Chesnais, Cedric B" uniqKey="Chesnais C" first="Cédric B" last="Chesnais">Cédric B. Chesnais</name><affiliation wicri:level="3"><nlm:affiliation>Institut de Recherche pour le Développement, UMI233/INSERM U1175, Université de Montpellier, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherche pour le Développement, UMI233/INSERM U1175, Université de Montpellier, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Weil, Gary J" sort="Weil, Gary J" uniqKey="Weil G" first="Gary J" last="Weil">Gary J. Weil</name><affiliation wicri:level="4"><nlm:affiliation>Infectious Diseases Division, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Infectious Diseases Division, Washington University School of Medicine, St Louis, MO</wicri:regionArea><placeName><region type="state">Missouri (État)</region><settlement type="city">Saint-Louis (Missouri)</settlement></placeName><orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName></affiliation></author><author><name sortKey="Fischer, Peter U" sort="Fischer, Peter U" uniqKey="Fischer P" first="Peter U" last="Fischer">Peter U. Fischer</name><affiliation wicri:level="4"><nlm:affiliation>Infectious Diseases Division, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Infectious Diseases Division, Washington University School of Medicine, St Louis, MO</wicri:regionArea><placeName><region type="state">Missouri (État)</region><settlement type="city">Saint-Louis (Missouri)</settlement></placeName><orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName></affiliation></author><author><name sortKey="Missamou, Francois" sort="Missamou, Francois" uniqKey="Missamou F" first="François" last="Missamou">François Missamou</name><affiliation wicri:level="1"><nlm:affiliation>Programme National de Lutte contre l'Onchocercose, Direction de l'Epidémiologie et de la Lutte contre la Maladie, Ministère de la Santé et de la Population, Brazzaville, Republic of the Congo.</nlm:affiliation><country xml:lang="fr">République du Congo</country><wicri:regionArea>Programme National de Lutte contre l'Onchocercose, Direction de l'Epidémiologie et de la Lutte contre la Maladie, Ministère de la Santé et de la Population, Brazzaville</wicri:regionArea><wicri:noRegion>Brazzaville</wicri:noRegion></affiliation></author><author><name sortKey="Boussinesq, Michel" sort="Boussinesq, Michel" uniqKey="Boussinesq M" first="Michel" last="Boussinesq">Michel Boussinesq</name><affiliation wicri:level="1"><nlm:affiliation>Programme National de Lutte contre l'Onchocercose, Direction de l'Epidémiologie et de la Lutte contre la Maladie, Ministère de la Santé et de la Population, Brazzaville, Republic of the Congo.</nlm:affiliation><country xml:lang="fr">République du Congo</country><wicri:regionArea>Programme National de Lutte contre l'Onchocercose, Direction de l'Epidémiologie et de la Lutte contre la Maladie, Ministère de la Santé et de la Population, Brazzaville</wicri:regionArea><wicri:noRegion>Brazzaville</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28372977</idno><idno type="pmid">28372977</idno><idno type="doi">10.1016/S1473-3099(17)30175-5</idno><idno type="wicri:Area/PubMed/Corpus">000266</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000266</idno><idno type="wicri:Area/PubMed/Curation">000266</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000266</idno><idno type="wicri:Area/PubMed/Checkpoint">000266</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000266</idno><idno type="wicri:Area/Ncbi/Merge">008F44</idno><idno type="wicri:Area/Ncbi/Curation">008F44</idno><idno type="wicri:Area/Ncbi/Checkpoint">008F44</idno><idno type="wicri:Area/Main/Merge">000620</idno><idno type="wicri:Area/Main/Curation">000619</idno><idno type="wicri:Area/Main/Exploration">000619</idno><idno type="wicri:Area/France/Extraction">000020</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo.</title><author><name sortKey="Pion, Sebastien D S" sort="Pion, Sebastien D S" uniqKey="Pion S" first="Sébastien D S" last="Pion">Sébastien D S. Pion</name><affiliation wicri:level="3"><nlm:affiliation>Institut de Recherche pour le Développement, UMI233/INSERM U1175, Université de Montpellier, Montpellier, France. Electronic address: sebastien.pion@ird.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherche pour le Développement, UMI233/INSERM U1175, Université de Montpellier, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Chesnais, Cedric B" sort="Chesnais, Cedric B" uniqKey="Chesnais C" first="Cédric B" last="Chesnais">Cédric B. Chesnais</name><affiliation wicri:level="3"><nlm:affiliation>Institut de Recherche pour le Développement, UMI233/INSERM U1175, Université de Montpellier, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherche pour le Développement, UMI233/INSERM U1175, Université de Montpellier, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Weil, Gary J" sort="Weil, Gary J" uniqKey="Weil G" first="Gary J" last="Weil">Gary J. Weil</name><affiliation wicri:level="4"><nlm:affiliation>Infectious Diseases Division, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Infectious Diseases Division, Washington University School of Medicine, St Louis, MO</wicri:regionArea><placeName><region type="state">Missouri (État)</region><settlement type="city">Saint-Louis (Missouri)</settlement></placeName><orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName></affiliation></author><author><name sortKey="Fischer, Peter U" sort="Fischer, Peter U" uniqKey="Fischer P" first="Peter U" last="Fischer">Peter U. Fischer</name><affiliation wicri:level="4"><nlm:affiliation>Infectious Diseases Division, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Infectious Diseases Division, Washington University School of Medicine, St Louis, MO</wicri:regionArea><placeName><region type="state">Missouri (État)</region><settlement type="city">Saint-Louis (Missouri)</settlement></placeName><orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName></affiliation></author><author><name sortKey="Missamou, Francois" sort="Missamou, Francois" uniqKey="Missamou F" first="François" last="Missamou">François Missamou</name><affiliation wicri:level="1"><nlm:affiliation>Programme National de Lutte contre l'Onchocercose, Direction de l'Epidémiologie et de la Lutte contre la Maladie, Ministère de la Santé et de la Population, Brazzaville, Republic of the Congo.</nlm:affiliation><country xml:lang="fr">République du Congo</country><wicri:regionArea>Programme National de Lutte contre l'Onchocercose, Direction de l'Epidémiologie et de la Lutte contre la Maladie, Ministère de la Santé et de la Population, Brazzaville</wicri:regionArea><wicri:noRegion>Brazzaville</wicri:noRegion></affiliation></author><author><name sortKey="Boussinesq, Michel" sort="Boussinesq, Michel" uniqKey="Boussinesq M" first="Michel" last="Boussinesq">Michel Boussinesq</name><affiliation wicri:level="1"><nlm:affiliation>Programme National de Lutte contre l'Onchocercose, Direction de l'Epidémiologie et de la Lutte contre la Maladie, Ministère de la Santé et de la Population, Brazzaville, Republic of the Congo.</nlm:affiliation><country xml:lang="fr">République du Congo</country><wicri:regionArea>Programme National de Lutte contre l'Onchocercose, Direction de l'Epidémiologie et de la Lutte contre la Maladie, Ministère de la Santé et de la Population, Brazzaville</wicri:regionArea><wicri:noRegion>Brazzaville</wicri:noRegion></affiliation></author></analytic><series><title level="j">The Lancet. Infectious diseases</title><idno type="eISSN">1474-4457</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Albendazole (administration & dosage)</term><term>Albendazole (therapeutic use)</term><term>Animals</term><term>Anthelmintics (administration & dosage)</term><term>Anthelmintics (therapeutic use)</term><term>Antiparasitic Agents (adverse effects)</term><term>Antiparasitic Agents (therapeutic use)</term><term>Child</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (parasitology)</term><term>Feces (parasitology)</term><term>Female</term><term>Helminthiasis (drug therapy)</term><term>Helminthiasis (parasitology)</term><term>Humans</term><term>Ivermectin (adverse effects)</term><term>Ivermectin (therapeutic use)</term><term>Loiasis (complications)</term><term>Male</term><term>Soil (parasitology)</term><term>Time Factors</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Albendazole (administration et posologie)</term><term>Albendazole (usage thérapeutique)</term><term>Animaux</term><term>Antihelminthiques (administration et posologie)</term><term>Antihelminthiques (usage thérapeutique)</term><term>Antiparasitaires (effets indésirables)</term><term>Antiparasitaires (usage thérapeutique)</term><term>Enfant</term><term>Facteurs temps</term><term>Femelle</term><term>Filariose lymphatique (parasitologie)</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Fèces (parasitologie)</term><term>Helminthiase (parasitologie)</term><term>Helminthiase (traitement médicamenteux)</term><term>Humains</term><term>Ivermectine (effets indésirables)</term><term>Ivermectine (usage thérapeutique)</term><term>Loase ()</term><term>Mâle</term><term>Sol (parasitologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Albendazole</term><term>Anthelmintics</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparasitic Agents</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="parasitology" xml:lang="en"><term>Soil</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term><term>Anthelmintics</term><term>Antiparasitic Agents</term><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Albendazole</term><term>Antihelminthiques</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Loiasis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Helminthiasis</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiparasitaires</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="parasitologie" xml:lang="fr"><term>Filariose lymphatique</term><term>Fèces</term><term>Helminthiase</term><term>Sol</term></keywords><keywords scheme="MESH" qualifier="parasitology" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Feces</term><term>Helminthiasis</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term><term>Helminthiase</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Albendazole</term><term>Antihelminthiques</term><term>Antiparasitaires</term><term>Ivermectine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Animals</term><term>Child</term><term>Female</term><term>Humans</term><term>Male</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Animaux</term><term>Enfant</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Loase</term><term>Mâle</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The standard treatment strategy of mass drug administration with ivermectin plus albendazole for lymphatic filariasis cannot be applied in central Africa, because of the risk of serious adverse events in people with high Loa loa microfilaraemia. Thus, alternative strategies are needed. We investigated one such alternative strategy for mass drug administration for elimination of lymphatic filariasis and soil-transmitted helminth infections in Republic of the Congo.</div></front></TEI><affiliations><list><country><li>France</li><li>République du Congo</li><li>États-Unis</li></country><region><li>Languedoc-Roussillon</li><li>Missouri (État)</li><li>Occitanie (région administrative)</li></region><settlement><li>Montpellier</li><li>Saint-Louis (Missouri)</li></settlement><orgName><li>École de médecine (Université Washington de Saint-Louis)</li></orgName></list><tree><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Pion, Sebastien D S" sort="Pion, Sebastien D S" uniqKey="Pion S" first="Sébastien D S" last="Pion">Sébastien D S. Pion</name></region><name sortKey="Chesnais, Cedric B" sort="Chesnais, Cedric B" uniqKey="Chesnais C" first="Cédric B" last="Chesnais">Cédric B. Chesnais</name></country><country name="États-Unis"><region name="Missouri (État)"><name sortKey="Weil, Gary J" sort="Weil, Gary J" uniqKey="Weil G" first="Gary J" last="Weil">Gary J. Weil</name></region><name sortKey="Fischer, Peter U" sort="Fischer, Peter U" uniqKey="Fischer P" first="Peter U" last="Fischer">Peter U. Fischer</name></country><country name="République du Congo"><noRegion><name sortKey="Missamou, Francois" sort="Missamou, Francois" uniqKey="Missamou F" first="François" last="Missamou">François Missamou</name></noRegion><name sortKey="Boussinesq, Michel" sort="Boussinesq, Michel" uniqKey="Boussinesq M" first="Michel" last="Boussinesq">Michel Boussinesq</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000020 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000020 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= France
|étape= Analysis
|type= RBID
|clé= pubmed:28372977
|texte= Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/RBID.i -Sk "pubmed:28372977" \
| HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |